Biomarkers of nivolumab benefit in resectable non-small cell lung cancer
Ranking
Overall
72
Content
75
Popularity
64
Observed public metrics from 1 member.
Merged summary
TL;DR - A Nature study analyzes CheckMate 77T trial participants to identify potential biomarkers predicting benefit from perioperative nivolumab in resectable non-small cell lung cancer. Such biomarkers could help select patients most likely to benefit from immunotherapy.
- Uses data from evaluable participants in the CheckMate 77T trial.
- Focuses on predictive biomarkers of perioperative nivolumab benefit.
- The provided abstract snippet does not specify the biomarkers, methods, or effect sizes.
Sources (1)
Biomarkers of nivolumab benefit in resectable non-small cell lung cancer
Public signals
OpenAlex citations 1
TL;DR - A Nature study analyzes CheckMate 77T trial participants to identify potential biomarkers predicting benefit from perioperative nivolumab in resectable non-small cell lung cancer. Such biomarkers could help select patients most likely to benefit from immunotherapy.
- Uses data from evaluable participants in the CheckMate 77T trial.
- Focuses on predictive biomarkers of perioperative nivolumab benefit.
- The provided abstract snippet does not specify the biomarkers, methods, or effect sizes.